Evidence map›Paper›PMID 30774597›Full record

ReviewFrontiers in pharmacology2019

PD-1/PD-L1 Inhibitors in Cervical Cancer.

Yuncong Liu, Li Wu, Ruizhan Tong, Feiyue Yang, Limei Yin, Mengqian Li, Liting You, Jianxin Xue, You Lu

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05437692 (A Prospective, Single Arm, Phase II Clinical Study on the Treatment of Locally Advanced Cervical Cancer), which is not on this map. Cited by 87 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 6 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05437692 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

A Prospective, Single Arm, Phase II Clinical Study on the Treatment of Locally Advanced Cervical Cancer (Ⅱ B to Ⅳ a) With Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2022 to 2025Enrolled19ConditionsLocally Advanced Cervical CancerArmszimberelimab combined With concurrent radiotherapy and chemotherapy
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 6 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Targeting innate immunity to overcome immune evasion in HPV-associated cancers.Frontiers in cellular and infection microbiology · 2026
    Review
  13. Observational
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yuncong LiuWest China School of Medicine, Sichuan University, Chengdu, China.
Li WuDepartment of Gynaecological Oncology, Guizhou Provincial People's Hospital, Guiyang, China.
Ruizhan TongWest China School of Medicine, Sichuan University, Chengdu, China.
Feiyue YangDepartment of Gynaecological Oncology, Guizhou Provincial People's Hospital, Guiyang, China.
Limei YinWest China School of Medicine, Sichuan University, Chengdu, China.
Mengqian LiWest China School of Medicine, Sichuan University, Chengdu, China.
Liting YouWest China School of Medicine, Sichuan University, Chengdu, China.
Jianxin XueWest China School of Medicine, Sichuan University, Chengdu, China.
You LuWest China School of Medicine, Sichuan University, Chengdu, China.
Sichuan University · CNGuizhou Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is one of the most common gynecological tumors, and the majority of early-stage cervical cancer patients achieve good recovery through surgical treatment and concurrent chemoradiotherapy (CCRT). However, for patients with recurrent, persistent, metastatic cervical cancer, effective treatment is rare, except for bevacizumab combined with chemotherapy. Programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors might be a novel choice to improve the clinical outcomes of these patients. Thus far, some pivotal trials, including Keynote 028, Keynote 158 and Checkmate 358, have indicated established clinical benefit of PD-1/PD-L1 inhibitors in cervical cancer. In light of these data, the FDA has approved pembrolizumab for patients with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy. There are also some ongoing studies that may provide more evidence for the PD-1/PD-L1 pathway as a therapeutic target in cervical cancer. In this review, we have summarized the status and application of PD-1/PD-L1 inhibitors in clinical trials for the treatment of cervical cancer and suggested some future directions in this field.

Indexed as

cervical cancerhuman papillomavirus (HPV)immune checkpoint inhibitorsimmunotherapyprogrammed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1)

Identifiers

PMID30774597
PMCPMC6367228
OpenAlexW2915035020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.